Rose T F, Ellis-Pegler R, Collins J, Small M
Infectious Diseases Unit, Auekland Hospital, New Zealand.
J Antimicrob Chemother. 1990 May;25(5):853-9. doi: 10.1093/jac/25.5.853.
Twenty-two (15 female and 7 male) patients with continuous ambulatory peritoneal dialysis (CAPD) associated peritonitis were entered into an open non-comparative evaluation of oral pefloxacin mesylate. An initial loading dose of 800 mg was followed by 400 mg twice daily. Five patients were subsequently excluded or withdrawn. The mean age of the patients was 44 +/- 12.6 years. All three Gram-negative infections (Escherichia coli, Acinetobacter calcoaceticus, Serratia liquefaciens) and all three culture negative infections were cured after 21 days treatment. In contrast one of four (25%) Staphylococcus aureus infections was cured, two persisted during treatment and one relapsed, after treatments of between 10 and 25 days. One of seven (14%) Staph. epidermidis infections was cured, three persisted and three relapsed after treatments of between nine and 25 days. Two of the five persistent isolates became resistant: all four relapsed isolates remained sensitive. Twelve of the 22 (55%) patients had 16 side effects, most commonly skin or musculo-skeletal. Three stopped pefloxacin because of them, though one had taken an excessive dose in error. Pefloxacin mesylate is not optimal treatment for Gram-positive coccal peritonitis in patients on CAPD, but its role in Gram-negative disease needs further evaluation.
22例（15例女性和7例男性）持续性非卧床腹膜透析（CAPD）相关腹膜炎患者进入了口服甲磺酸培氟沙星的开放性非对照评估。初始负荷剂量为800mg，随后每日两次，每次400mg。5例患者随后被排除或退出。患者的平均年龄为44±12.6岁。所有3例革兰氏阴性菌感染（大肠杆菌、醋酸钙不动杆菌、液化沙雷氏菌）和所有3例培养阴性感染在治疗21天后均治愈。相比之下，4例金黄色葡萄球菌感染中有1例（25%）治愈，2例在治疗期间持续存在，1例在10至25天的治疗后复发。7例表皮葡萄球菌感染中有1例（14%）治愈，3例持续存在，3例在9至25天的治疗后复发。5例持续分离株中有2例产生耐药：所有4例复发分离株仍敏感。22例患者中有12例（55%）出现16次副作用，最常见的是皮肤或肌肉骨骼方面。3例因这些副作用停用了培氟沙星，不过其中1例是误服了过量药物。甲磺酸培氟沙星并非CAPD患者革兰氏阳性球菌性腹膜炎的最佳治疗药物，但其在革兰氏阴性菌疾病中的作用需要进一步评估。
